Direct comparison of aspirin plus hirudin aspirin plus heparin, and aspirin alone among 12,000 patients with acute myocardial infarction not receiving thrombolysis: Rationale and design of the First American Study of Infarct Survival (ASIS-1) Paul M. RidkerChristopher J. O'DonnellCharles H. Hennekens Featured Contribution Pages: 119 - 124
Hemostatic factors and ischemic heart disease risk among postmenopausal women Elaine N. Meilahn Frontiers in Thrombocardiology Pages: 125 - 131
Improving the efficacy and stability of coronary reperfusion following thrombolysis: Exploring the thrombin hypothesis Richard C. Becker Frontiers in Thrombocardiology Pages: 133 - 144
Novel and innovative dosing regimens in thrombolytic therapy for acute myocardial infarction J. A. Purvis Frontiers in Thrombocardiology Pages: 145 - 151
The heparin rebound phenomenon—Does it offer insights toward understanding the pathobiology of coronary thrombosis and its treatment? Richard C. Becker Editorial Pages: 157 - 161
Effects of a novel leumedin NPC 15669 on myocardial stunning and preconditioned infarction size in swine William R. HerzogPaul A. GurbelVictor L. Serebruany Basic Research Pages: 163 - 170
NPC 15669, an antiinflammatory leucine derivative, reduces in vitro platelet aggregability in both swine and human plasma Victor L. SerebruanyWilliam R. HerzogRobert A. Vogel Basic Research Pages: 171 - 178
Neutrophil and platelet activity and quantification following delayed tPA therapy in a rabbit model of thromboembolic stroke Martin M. BednarRichard H. DooleyCordell E. Gross Basic Research Pages: 179 - 185
Regional and systemic platelet function is altered by myocardial ischemia-reperfusion Paul A. GurbelVictor L. SerebruanyWilliam R. Herzog Basic Research Pages: 187 - 194
Changes in the use of thrombolytic therapy in Seattle area hospitals from 1988 to 1992: Results from the myocardial infarction triage and intervention registry Charles MaynardJenny S. MartinW. Douglas Weaver Clinical Investigation and Epidemiology Pages: 195 - 199
Clinical experience with routine activated coagulation time monitoring during elective PTCA Stephen J. VoyceLouis I. HellerRichard C. Becker Clinical Investigation and Epidemiology Pages: 201 - 206
Key references: Antiplatelet therapy as an adjunct to thrombolysis and coronary angioplasty James E. Tcheng State-of-the-Art Pages: 213 - 216